外用西罗莫司溶液治疗儿童及成人舌微囊型淋巴管畸形(TOPGUN):多中心、随机、评估者盲、对照、阶梯楔形临床试验的研究方案
TOPGUN为多中心随机评估者盲对照阶梯楔形试验,评估1 mg/mL西罗莫司溶液每日一次外用对比常规护理(不治疗)对儿童及成人舌微囊型淋巴管畸形的疗效与安全性,主要结局为盲法专家基于每月标准化照片的PGA 0-5分评估,计划随访24周。
要点
- TOPGUN试验评估1 mg/mL西罗莫司溶液每日一次外用治疗舌微囊型淋巴管畸形。
- 采用个体随机阶梯楔形设计,对照为常规护理(不治疗),随访24周。
- 主要结局为3名独立盲法专家基于每月标准化照片的PGA 0-5分评估。
核心结论
- 若外用西罗莫司的疗效与安全性得到证实,其可能成为舌微囊型淋巴管畸形的一线治疗。
研究设计与样本
- 多中心、随机、评估者盲、对照、个体随机阶梯楔形临床试验,随访24周,比较1 mg/mL西罗莫司溶液每日一次外用与常规护理(不治疗)。
- 参与者先进入观察期,随后在随机时间点(第0、4、8或12周)切换至干预,每4周访视一次(在研究中心的面对面访视或远程会诊)。
主要发现
- 主要结局为3名独立盲法专家使用PGA 0-5分量表对每月标准化照片评估舌微囊型淋巴管畸形的整体严重程度。
- 次要结局包括病灶大小测量和生活质量评估,以及研究者与患者评估的总体疾病和特定症状(渗液、出血、流涎、进食障碍、味觉改变、美观损害、疼痛和整体不适)。
- 进行生物学监测,包括残余血西罗莫司浓度和常规实验室参数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations presenting as clusters of cysts filled with lymph fluid or blood. Even small well-limited lesions can be responsible for a heavy burden, inducing pain, aesthetic prejudice, or oozing, bleeding, infections. The natural history of LMLMs is progressive worsening punctuated by acute flares. Therapeutic options include surgery, laser excision, and radiofrequency ablation but all are potentially detrimental and expose to local relapse. Therefore, the management frequently relies on a "watchful waiting" approach. In complicated LMLMs, treatment with oral sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is often used. Topical applications of sirolimus on the buccal mucosae have been reported in other oral diseases with good tolerance and none to slight detectable blood sirolimus concentrations. We aim to evaluate the efficacy and safety of a 1 mg/mL sirolimus solution applied once daily on LMLM of any stage in children and adults after 4, 8, 12, 16, 20, and 24 weeks of treatment compared to usual care (no treatment). METHODS: This is a randomized, multicentric study using an individually randomized stepped-wedge design over 24 weeks to evaluate topical application of a 1 mg/mL sirolimus solution once daily, on LMLM, versus usual care (no treatment), the control condition. Participants begin with an observational period and later switch to the intervention at a randomized time (week 0, 4, 8, or 12). Visits occur every 4 weeks, either in the study center or by teleconsulting. The primary outcome will be the evaluation of global severity of the LMLM on monthly standardized photographs by 3 independent blinded experts using the physical global assessment (PGA) 0 to 5 scale. Secondary outcomes will include lesion size measurement and quality of life assessment, investigator, and patient-assessed global disease and specific symptoms (oozing, bleeding, sialorrhea, eating impairment, taste modification, aesthetic impairment, pain, and global discomfort) assessment. A biological monitoring will be performed including residual blood sirolimus concentration and usual laboratory parameters. DISCUSSION: Given the disappointing state of current treatment options in LMLMs, topical sirolimus could become firstline therapy in treating LMLMs if its efficacy and safety were to be demonstrated. TRIAL REGISTRATION: ClinicalTrials.gov NCT04128722 . Registered on 24 September 2019. EudraCT: EUCTR2019-001530-33-FR Sponsor (University Hospital Center of Tours - CHRU Tours): DR190041-TOPGUN French regulatory authorities: ID RCB: 2019-001530-33.
引用
- Marchand A, Caille A, Gissot V, et al. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial. Trials. 2022. PMID: 35804404. doi:10.1186/s13063-022-06365-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。